On Apr. 19, 2022, Moderna announced new clinical data on its bivalent COVID-19 booster platform including data on the Company’s first bivalent booster candidate, mRNA-1273.211, which includes mutations found in the Beta variant of concern, several of which had been persistent in more recent variants of concern including Omicron.

A 50 ﾵg booster dose of mRNA-1273.211 demonstrated superiority against Beta, Delta and Omicron variants of concern one month after administration. Superiority continued six months after administration for Beta and Omicron variants of concern as well. A 50 ﾵg booster dose of mRNA-1273.211 was generally well tolerated with a reactogenicity profile comparable to a booster dose of mRNA-1273 at the 50 ﾵg dose level. The manuscript was available as a preprint through Research Square.